Literature DB >> 16943588

Expression and functional analysis of menin in a multiple endocrine neoplasia type 1 (MEN1) patient with somatic loss of heterozygosity in chromosome 11q13 and unidentified germline mutation of the MEN1 gene.

Junko Naito1, Hiroshi Kaji, Hideaki Sowa, Riko Kitazawa, Sohei Kitazawa, Toshihiko Tsukada, Geoffrey N Hendy, Toshitsugu Sugimoto, Kazuo Chihara.   

Abstract

In some patients with multiple endocrine neoplasia type 1 (MEN1) it is not possible to identify a germline mutation in the MEN1 gene. We sought to document the loss of expression and function of the MEN1 gene product, menin, in the tumors of such a patient. The proband is an elderly female patient with primary hyperparathyroidism, pancreatic islet tumor, and breast cancer. Her son has primary hyperparathyroidism. No germline MEN1 mutation was identified in the proband or her son. However, loss of heterozygosity at the MEN1 locus and complete lack of menin expression were demonstrated in the proband's tumor tissue. The proband's cultured parathyroid cells lacked the normal reduction in proliferation and parathyroid hormone secretion in response to transforming growth factor- beta. This assessment provided insight into the molecular pathogenesis of the patient and provides evidence for a critical requirement for menin in the antiproliferative action of transforming growth factor-beta.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16943588     DOI: 10.1385/ENDO:29:3:485

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  35 in total

1.  Clinical testing for multiple endocrine neoplasia type 1 in a DNA diagnostic laboratory.

Authors:  Roger D Klein; Sana Salih; Jesse Bessoni; Allen E Bale
Journal:  Genet Med       Date:  2005-02       Impact factor: 8.822

2.  A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors.

Authors:  J S Crabtree; P C Scacheri; J M Ward; L Garrett-Beal; M R Emmert-Buck; K A Edgemon; D Lorang; S K Libutti; S C Chandrasekharappa; S J Marx; A M Spiegel; F S Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

Review 3.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

4.  Role of transforming growth factor-beta signaling in cancer.

Authors:  M P de Caestecker; E Piek; A B Roberts
Journal:  J Natl Cancer Inst       Date:  2000-09-06       Impact factor: 13.506

5.  Somatic mutations in MEN type 1 tumors, consistent with the Knudson "two-hit" hypothesis.

Authors:  A A Pannett; R V Thakker
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

6.  Alterations of the MEN1 gene in sporadic parathyroid tumors.

Authors:  F Farnebo; B T Teh; S Kytölä; A Svensson; C Phelan; K Sandelin; N W Thompson; A Höög; G Weber; L O Farnebo; C Larsson
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

7.  Of mice and MEN1: Insulinomas in a conditional mouse knockout.

Authors:  Judy S Crabtree; Peter C Scacheri; Jerrold M Ward; Sara R McNally; Gary P Swain; Cristina Montagna; Jeffrey H Hager; Douglas Hanahan; Helena Edlund; Mark A Magnuson; Lisa Garrett-Beal; A Lee Burns; Thomas Ried; Settara C Chandrasekharappa; Stephen J Marx; Allen M Spiegel; Francis S Collins
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

8.  Multiple endocrine neoplasia type 1 with unusual concomitance of various neoplastic disorders.

Authors:  Yoshihiro Nishimura; Koh Yamashita; Wataru Yumita; Masanori Yamazaki; Miyuki Katai; Akihiro Sakurai; Kiyoshi Hashizume
Journal:  Endocr J       Date:  2004-02       Impact factor: 2.349

9.  Clinical and genetic features of patients with multiple endocrine tumors who have neither family history nor MEN1 germline mutations.

Authors:  Akihiro Sakurai; Miyuki Katai; Wataru Yumita; Kesami Minemura; Kiyoshi Hashizume
Journal:  Endocrine       Date:  2004-02       Impact factor: 3.633

10.  Differential expression of menin in sporadic pituitary adenomas.

Authors:  M Theodoropoulou; I Cavallari; L Barzon; D M D'Agostino; T Ferro; T Arzberger; Y Grübler; L Schaaf; M Losa; F Fallo; V Ciminale; G K Stalla; U Pagotto
Journal:  Endocr Relat Cancer       Date:  2004-06       Impact factor: 5.678

View more
  2 in total

1.  Impaired transforming growth factor-β (TGF-β) transcriptional activity and cell proliferation control of a menin in-frame deletion mutant associated with multiple endocrine neoplasia type 1 (MEN1).

Authors:  Lucie Canaff; Jean-François Vanbellinghen; Hiroshi Kaji; David Goltzman; Geoffrey N Hendy
Journal:  J Biol Chem       Date:  2012-01-24       Impact factor: 5.157

Review 2.  Menin and bone metabolism.

Authors:  Hiroshi Kaji
Journal:  J Bone Miner Metab       Date:  2012-04-28       Impact factor: 2.626

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.